Sipuleucel-T: a therapeutic cancer vaccine for the treatment of castration- or hormone-refractory prostate cancer.

Abstract

Sipuleucel-T is a therapeutic cancer vaccine approved for the treatment of castration- or hormone-refractory prostate cancer. Through a novel process, it activates the body's own antigen-presenting cells to induce an immune response to prostatic acid phosphatase, a protein found on prostate cancer cells. A treatment course consists of three total infusions spread 2 weeks apart. Throughout all phases of clinical trials, sipuleucel-T has been shown to be safe and well tolerated. Sipuleucel-T has demonstrated an ability to increase overall survival by approximately 4 months when compared with placebo. However, sipuleucel-T has not shown any improvement in affecting patients' time to disease progression.

• Authors: Marilyn N Bulloch, Mohammed M Elayan, Holly R Renfroe
• Journal: Expert review of clinical pharmacology (Expert Rev Clin Pharmacol) Vol. 4 Issue 6 Pg. 685-92 (Nov 2011) ISSN: 1751-2441 [Electronic] England
• PMID: 22111853 (Publication Type: Journal Article)

Chemical References

• Cancer Vaccines
• Tissue Extracts
• sipuleucel-T
• Acid Phosphatase
• prostatic acid phosphatase
• Protein Tyrosine Phosphatases

Topics

• Acid Phosphatase
• Animals
• Cancer Vaccines (administration & dosage, immunology)
• Clinical Trials as Topic (methods)
• Drug Administration Schedule
• Humans
• Male
• Orchiectomy
• Prostatic Neoplasms (enzymology, pathology, prevention & control)
• Protein Tyrosine Phosphatases (immunology)
• Tissue Extracts (administration & dosage, immunology)
• Treatment Outcome